CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Natera Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Natera Inc
13011 MCCALLEN PASS
BUILDING A SUITE 100
Phone: (650) 249-9090p:650 249-9090 AUSTIN, TX  78753  United States Ticker: NTRANTRA
Business Summary
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
8071 Medical laboratories
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research
7372 Prepackaged software
7374 Computer processing and data preparation and processing services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Co-Founder MatthewRabinowitz 51 1/2/2019 1/1/2005
President, Chief Business Officer JohnFesko 45 9/18/2023 9/18/2023
Chief Executive Officer, Director Steven L.Chapman 45 9/18/2023 12/1/2010
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Natera International, Inc.
NTRA

General Information
Number of Employees: 4,424 (As of 12/31/2024)
Outstanding Shares: 135,186,184 (As of 2/21/2025)
Shareholders: 20
Stock Exchange: NASD
Federal Tax Id: 010894487
Fax Number: (302) 674-5266
Email Address: info@genesecurity.net


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 8, 2025